Clinical Trial Update: Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Lutetium-177-PSMA radioligand therapy for advanced salivary gland cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma
• Salivary Duct Carcinoma
• Salivary Gland Cancer

Drugs mentioned

• Lutetium-177-PSMA radioligand therapy

Snippet

Sponsor: Radboud University Medical Center | Conditions: Salivary Gland Cancer, Salivary Duct Carcinoma | Phase 2 | Status: COMPLETED